印度合同制药物制造部门每年增长13%,到2029年达到15.4B美元,受全球外包和供应链转移的驱动。 India’s contract drug manufacturing sector to grow 13% annually, reaching $15.4B by 2029, driven by global outsourcing and supply chain shifts.

印度的CRDMO部门预计将增长13%,从2024年增长到2029年,达到154亿美元,全球市场份额上升到5%,其驱动因素是制药外包、复杂的毒品需求以及“中国+1”战略。 India’s CRDMO sector is projected to grow at a 13% CAGR from 2024 to 2029, reaching $15.4 billion, with its global market share rising to 5%, driven by pharmaceutical outsourcing, complex drug demand, and the "China+1" strategy. 该国的优势包括大量STEM毕业生、成本低、严格遵守规章、以及美国经林业发展局核准的全世界最先进的API设施。 The country’s advantages include a large pool of STEM graduates, lower costs, strong regulatory compliance, and the most U.S. FDA-approved API facilities worldwide. 印度公司在不断增长的投资和全球供应链多样化的支持下,正在从基本制造业向综合研究与商业服务推进。 Indian firms are advancing from basic manufacturing to integrated research-to-commercial services, supported by growing investment and global supply chain diversification.